Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Analyst Ratings
Werewolf Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Eli Lilly & Co (LLY) and Envista Holdings (NVST)
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Werewolf Therapeutics (HOWL)
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Werewolf Therapeutics Analyst Ratings
Buy Rating Justified by Werewolf Therapeutics' Advancements in WTX-124 With Promising Efficacy and Safety Profile
Werewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline Potential
Werewolf Therapeutics Analyst Ratings
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical Updates
Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Werewolf Therapeutics Analyst Ratings
Buy Rating Affirmed for Werewolf Therapeutics With Anticipated Surge on WTX-124 Phase 1 Data Release
Buy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform Developments
Analysts' Top Healthcare Picks: Werewolf Therapeutics (HOWL), AbbVie (ABBV)
Promising Preliminary Phase 1 Data and Strong INDUKINE Platform Basis for Buy Rating on Werewolf Therapeutics: A Leerink Partners Analysis
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target